Hyperthyroidism affects about 1.2% of the US population. About half of these cases have obvious symptoms while the other half do not. It occurs between two and ten times more often in women. The disease is more common in those over the age of 60 years. Treatment depends partly on the cause and severity of disease. We focus on TSHR protein. Protein modeling could be of direct benefit to structure-based drug designing and the modeled protein would act as a potential target for drug docking. With the help of antigenic binding sites prediction we can understand the function of the sequences. Thus, we finally conclude that the modeled protein and the antigenic binding sites prediction would of use to immunomedicine and to those who are interested in research on hyperthyroidism disorder.